Lithocholic acid

CAT:
804-HY-B0172-01
Size:
500 mg
  • Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
  • Dry Ice Shipment: No
Lithocholic acid - image 1

Lithocholic acid

  • UNSPSC Description:

    Lithocholic acid is a toxic secondary bile acid that can promote intrahepatic cholestasis and promote tumorigenesis. Lithocholic acid is also a FXR antagonist and a PXR/SXR agonist[1][2][3][4][5].
  • Target Antigen:

    Apoptosis; Autophagy; Endogenous Metabolite; FXR
  • Type:

    Natural Products
  • Related Pathways:

    Apoptosis;Autophagy;Metabolic Enzyme/Protease
  • Applications:

    Metabolism-sugar/lipid metabolism
  • Field of Research:

    Cancer; Metabolic Disease
  • Assay Protocol:

    https://www.medchemexpress.com/Lithocholic-acid.html
  • Purity:

    99.99
  • Solubility:

    DMSO : 250 mg/mL (ultrasonic)|Ethanol : 10 mg/mL (ultrasonic;warming;heat to 60°C)|H2O : 0.99 mg/mL (ultrasonic;warming;adjust pH to 11 with NaOH;heat to 60°C)
  • Smiles:

    C[C@@]12[C@](CC[C@]2([H])[C@H](C)CCC(O)=O)([H])[C@@]3([H])[C@]([C@@]4([C@](C[C@H](O)CC4)([H])CC3)C)([H])CC1
  • Molecular Weight:

    376.57
  • References & Citations:

    [1]Jenkins, D.J., et al., Effect on blood lipids of very high intakes of fiber in diets low in saturated fat and cholesterol. N Engl J Med, 1993. 329(1): p. 21-6.|[2]Goldberg, A.A., et al., Lithocholic bile acid selectively kills neuroblastoma cells, while sparing normal neuronal cells. Oncotarget, 2011. 2(10): p. 761-82.|[3]Matsubara, T., et al., TGF-beta-SMAD3 signaling mediates hepatic bile acid and phospholipid metabolism following lithocholic acid-induced liver injury. J Lipid Res, 2012. 53(12): p. 2698-707.|[4]Yang R, et al. Metabolomic analysis of cholestatic liver damage in mice. Food Chem Toxicol. 2018 Jul 14;120:253-260.|[5]Yu J, et al. Lithocholic acid decreases expression of bile salt export pump through farnesoid X receptor antagonist activity. J Biol Chem. 2002 Aug 30;277(35):31441-7.
  • Shipping Conditions:

    Room Temperature
  • Storage Conditions:

    -20°C, 3 years; 4°C, 2 years (Powder)
  • Clinical Information:

    Phase 3
  • CAS Number:

    434-13-9